T1	condition 0 36	Anthracycline-induced cardiotoxicity
T4	total-participants 542 544	96
T5	age 564 572	47 years
T6	eligibility 574 694	with BC after breast surgery, without significant cardiovascular diseases, who were eligible for adjuvant anthracyclines
T7	control 734 745	control arm
T9	outcome 1156 1184	LVEF above 10‑percent points
T10	iv-bin-percent 1197 1201	6.3%
T11	cv-bin-percent 1227 1232	18.5%
T13	outcome 1332 1385	percentage of patients with elevated NT‑proBNP levels
T14	outcome 1514 1530	NT‑proBNP levels
T2	intervention 53 101	angiotensin-converting enzyme inhibitor ramipril
T3	outcome 1268 1270	HF
T8	outcome 1272 1285	cardiac death
T12	outcome 1290 1294	LVEF
